Pharmaceuticals, Biotechnology and Life Sciences
—Phase 1 dose escalation of H3B-6545, a potential first-in-class Selective ERα Covalent Antagonist (SERCA), in women with ER-positive, HER2-negative breast…
A top influencer among Entrepreneurs in the healthcare industry today WATERTOWN, Mass.–(BUSINESS WIRE)–InCrowd, pioneer of the real-time market intelligence platform…
LONDON–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/Biotechnology?src=hash" target="_blank"gt;#Biotechnologylt;/agt;–The global chemotherapy treatment market is expected to post a CAGR of close to 3% during the…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that new data from…
— New Drug Application for investigational product HP-3070 under FDA review — MIAMI & JERSEY CITY, N.J.–(BUSINESS WIRE)–Noven Pharmaceuticals, Inc.,…
LAVAL, Quebec–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/Altasciences?src=hash" target="_blank"gt;#Altascienceslt;/agt;–Altasciences, a mid-size CRO specializing in a flexible, innovative approach to providing comprehensive early stage drug…
Additional follow-up from the completed Phase 1/2 Northstar (HGB-204) study of LentiGlobin in adolescents and adults with TDT New data…
EDINBURGH, Scotland–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/PromPT?src=hash" target="_blank"gt;#PromPTlt;/agt;–Synpromics Ltd, the leader in gene control, and Lonza Pharma & Biotech announce a partnership for…
Partnership creates promise for improving the health of those living with this debilitating and costly disease SAN FRANCISCO–(BUSINESS WIRE)–Virta Health,…
U.S. FDA Remains Committed to Streamline & Accelerate Drug Development using Model-Informed Drug Development (MIDD) technology RESEARCH TRIANGLE PARK, N.C.–(BUSINESS…